DOCSLIB.ORG

Nmda-Receptor-Glycine.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nmda-Receptor-Glycine.Pdf Neuropharmacology 55 (2008) 1238–1250 Contents lists available at ScienceDirect Neuropharmacology journal homepage: www.elsevier.com/locate/neuropharm A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral–CA1 synapses in hippocampus Xiao-lei Zhang a, John A. Sullivan a, Joseph R. Moskal b, Patric K. Stanton a,c,* a Department of Cell Biology & Anatomy, New York Medical College, Basic Sciences Building, Room 217, Valhalla, NY 10595, USA b The Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, McCormick School of Engineering and Applied Sciences, Northwestern University, Evanston, IL 60201, USA c Department of Neurology, New York Medical College, Valhalla, NY 10595, USA article info abstract 2þ Article history: N-methyl-D-aspartate glutamate receptors (NMDARs) are a key route for Ca influx into neurons Received 13 June 2008 important to both activity-dependent synaptic plasticity and, when uncontrolled, triggering events that Received in revised form 18 July 2008 cause neuronal degeneration and death. Among regulatory binding sites on the NMDAR complex is Accepted 4 August 2008 a glycine binding site, distinct from the glutamate binding site, which must be co-activated for NMDAR channel opening. We developed a novel glycine site partial agonist, GLYX-13, which is both nootropic and Keywords: neuroprotective in vivo. Here, we assessed the effects of GLYX-13 on long-term synaptic plasticity and Glutamate receptor NMDAR transmission at Schaffer collateral–CA1 synapses in hippocampal slices in vitro.GLYX-13 Learning Memory simultaneously enhanced the magnitude of long-term potentiation (LTP) of synaptic transmission, while N-methyl-D-aspartate receptor reducing long-term depression (LTD). GLYX-13 reduced NMDA receptor-mediated synaptic currents in Partial agonist CA1 pyramidal neurons evoked by low frequency Schaffer collateral stimulation, but enhanced NMDAR Glycine currents during high frequency bursts of activity, and these actions were occluded by a saturating Synaptic plasticity concentration of the glycine site agonist D-serine. Direct two-photon imaging of Schaffer collateral burst- evoked increases in [Ca2þ] in individual dendritic spines revealed that GLYX-13 selectively enhanced burst-induced NMDAR-dependent spine Ca2þ influx. Examining the rate of MK-801 block of synaptic versus extrasynaptic NMDAR-gated channels revealed that GLYX-13 selectively enhanced activation of burst-driven extrasynaptic NMDARs, with an action that was blocked by the NR2B-selective NMDAR antagonist ifenprodil. Our data suggest that GLYX-13 may have unique therapeutic potential as a learning and memory enhancer because of its ability to simultaneously enhance LTP and suppress LTD. Ó 2008 Elsevier Ltd. All rights reserved. 1. Introduction et al., 1990; Falls et al., 1992), maintaining the epileptic state after kindling (Yeh et al., 1989), reducing the negative symptoms of N-methyl-D-aspartate receptors (NMDARs) have well estab- schizophrenics (Heresco-Levy et al., 2002; Evins et al., 2002), and lished roles in synaptic plasticity, causing the induction of some reducing morphine-induced tolerance (Quartaroli et al., 2001). forms of both LTP and LTD of synaptic strength (Collingridge et al., Although the stoichiometry of native NMDARs is still uncertain, 1983; Dudek and Bear,1992; Huang et al., 2005; Stanton et al., 2003, recombinant NMDARs appear to consist of at least one NR1 and one 2005). This receptor–ionophore complex is functionally involved in NR2 subunit, and most evidence now suggests that NMDARs regulating glutamate-induced excitotoxic neuronal cell death, assemble as tetramers containing 2 NR1 and 2 NR2 subunits attenuating neuropathic pain in rat models measuring mechanical (whenever the NR3 subunit is not expressed; see Prybylowski and allodynia (Dickenson and Aydar, 1991; Laird et al., 1996), promoting Wenthold, 2004; Paoletti and Neyton, 2007). There are multiple the acquisition and extinction of conditioned fear (Miserendino forms of both NR2 (A–D) and NR3 (A and B) subunits, and at least 8 splice variants of NR1. Moreover, NMDAR expression is develop- mentally regulated and differentially distributed in different brain regions. NMDARs are part of a family of ionotropic glutamate * Corresponding author. Department of Cell Biology & Anatomy, New York receptors that include kainate and (AMPA) receptors. Kainate and Medical College, Basic Sciences Building, Room 217, Valhalla, NY 10595, USA. Tel.: þ1 914 594 4883; fax: þ1 914 594 4653. AMPA receptors are each ligand-gated ion channels that, upon þ þ E-mail address: [email protected] (P.K. Stanton). activation, gate the flux of K and Na ions (though some AMPA 0028-3908/$ – see front matter Ó 2008 Elsevier Ltd. All rights reserved. doi:10.1016/j.neuropharm.2008.08.018 X.-lei Zhang et al. / Neuropharmacology 55 (2008) 1238–1250 1239 receptor subunits confer significant Ca2þ permeability; Hollmann transferred to an interface holding chamber for incubation at room temperature for et al., 1991). In contrast, the NMDA receptor–ion channel complex a minimum of 1 h before commencing recording. opens a channel with significant Ca2þ permeability. The NMDA receptor–ionophore complex is unique among 2.2. Extracellular recordings glutamate receptors in requiring binding of both glutamate and Slices were transferred to an interface recording chamber and continuously glycine for activation. While glutamate binding during synaptic perfused at 3 ml/min with oxygenated ACSF at 32 Æ 0.5 C. Low resistance recording transmission causes channel opening, tonic binding of endogenous electrodes were made from thin-walled borosilicate glass (1–2 MU after filling with agonists of the glycine site is also necessary for glutamate-driven ACSF) and inserted into the apical dendritic region of the Schaffer collateral termi- nation field in stratum radiatum of the CA1 region to record field excitatory post- opening to occur (Forsythe et al., 1988; Kleckner and Dingledine, synaptic potentials (fEPSPs). A bipolar stainless steel stimulating electrode (FHC Co.) 1988). Moreover, there are various modulatory sites on the complex was placed on Schaffer collateral–commissural fibers in CA3 stratum radiatum, and that can modulate function, including a Mg2þ site located within constant current stimulus intensity adjusted to evoke approximately half-maximal the channel that causes the voltage-dependence of NMDARs, and fEPSPs once each 30 s (50–100 pA; 100 ms duration). fEPSP slope was measured by proton sensor, polyamine and Zn2þ sites found on various subunits linear interpolation from 20–80% of maximum negative deflection, and slopes confirmed to be stable to within Æ10% for at least 10 min before commencing an (Mayer et al., 1992). experiment. Signals were recorded using a Multiclamp 700B amplifier and digitized While there are many glutamate receptors found in the central with a Digidata 1322 (Axon Instruments, Foster City, CA). Data were analyzed using nervous system, the strychnine-insensitive glycine site is unique to pClamp software (version 9, Axon Instruments) on an IBM-compatible personal the NMDA receptor. This, together with the number of clinically computer. relevant functions that NMDA receptors play, has made the glycine site an important target for drug development (see Wood, 2005 for 2.3. Intracellular recordings review). For example, the glycine site partial agonist, D-cycloserine Patch pipettes were pulled from borosilicate glass (1B150F-4, World Precision (DCS), has been shown to have cognitive-enhancing properties in Instruments) using a flaming/brown micropipette puller (P-97, Sutter Instruments). vivo (Hood et al., 1989; Monaghan et al., 1988; Flood et al., 1992; The composition of the patch pipette solution for NMDA current recordings was (in Schuster and Schmidt, 1992; Thompson et al., 1992) as has the mM): 135 mM CsMeSO3, 8 mM NaCl, 10 HEPES, 2 Mg-ATP, 0.3 Na-GTP, 0.5 EGTA, 1 QX-314. The patch pipette solution pH was adjusted to 7.25 with CsOH, and had an glycine prodrug, milacemide (Handelmann et al., 1989; Quarter- osmolarity of 280 Æ 10 mOsm. When filled with this solution, patch pipettes had tip main et al.,1991; Schwartz et al.,1991,1992; Finkelstein et al.,1994). resistances of 5–6 MU. Both of these compounds, however, appear to result in desensiti- Whole cell patch clamp recordings were obtained from CA1 pyramidal neurons zation with chronic administration (Herting, 1991; Quartermain in slices in a fully submerged recording chamber at room temperature, and 95% O2/ et al.,1994). Recently, Tuominen et al. (2005) found that glycine and 5% CO2 was passed over the perfusate to ensure an oxygenated local environment. The submerged recording chamber was mounted on a Zeiss Axioskop 2 FS upright D-serine, but not the partial agonist DCS, are effective at reducing microscope equipped with infrared differential interference contrast (DIC) optics. some of the negative symptoms of schizophrenia when used to Pyramidal neurons of the hippocampal CA1 region were visualized with a 63Â water augment antipsychotic therapeutics. immersion lens, and patched in the voltage-clamp configuration. Excitatory post- synaptic currents (EPSCs) were recorded using a MultiClamp 700B (Axon Instru- Glyxins are a new family of glycine site-specific, N-methyl-D- ments, Foster City, CA), with the low-pass filter setting at 1–3 kHz, series resistance aspartate receptor modulators. They were generated from an amino was compensated in the voltage-clamp
Load more

Recommended publications
  • Seizure Disorders and Commercial Motor Vehicle Driver Safety (Comprehensive Review)
    Evidence Report: Seizure Disorders and Commercial Motor Vehicle Driver Safety (Comprehensive Review) Presented to Federal Motor Carrier Safety Administration November 30, 2007 Prepared for Prepared by MANILA Consulting Group, Inc. ECRI 1420 Beverly Road, Suite 220 5200 Butler Pike McLean, VA 22101 Plymouth Meeting, PA 19462 This report is comprised of research conducted to analyze the impact of Seizure Disorders on Commercial Motor Vehicle Driver Safety. Federal Motor Carrier Safety Administration considers evidence, expert recommendations, and other data, however, all proposed changes to current standards and guidance (guidelines) will be subject to public-notice-and-comment and regulatory processes. FMCSA Evidence Report: Seizure Disorders and Commercial Motor Vehicle Driver Safety 11/30/2007 Policy Statement This evidence report was prepared by ECRI under subcontract to MANILA Consulting Group, Inc., which holds prime Contract No: GS-10F-0177N/DTMC75-06-F-00039 with the Department of Transportation’s Federal Motor Carrier Safety Administration. ECRI is an independent, nonprofit health services research agency and a Collaborating Center for Health Technology Assessment of the World Health Organization. ECRI has been designated an Evidence-based Practice Center (EPC) by the United States Agency for Healthcare Research and Quality. ECRI’s mission is to provide information and technical assistance to the healthcare community worldwide to support safe and cost-effective patient care. The results of ECRI’s research and experience are available through its publications, information systems, databases, technical assistance programs, laboratory services, seminars, and fellowships. The purpose of this evidence report is to provide information regarding the current state of knowledge on this topic.
    [Show full text]
  • RR5211-Front Cover-TB.Pmd
    Morbidity and Mortality Weekly Report Recommendations and Reports June 20, 2003 / Vol. 52 / No. RR-11 Treatment of Tuberculosis American Thoracic Society, CDC, and Infectious Diseases Society of America INSIDE: Continuing Education Examination department of health and human services Centers for Disease Control and Prevention MMWR CONTENTS The MMWR series of publications is published by the Purpose ............................................................................... 1 Epidemiology Program Office, Centers for Disease What’s New In This Document ............................................. 1 Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333. Summary ............................................................................. 1 1. Introduction and Background ......................................... 13 SUGGESTED CITATION 2. Organization and Supervision of Treatment ................... 15 Centers for Disease Control and Prevention. 3. Drugs in Current Use ..................................................... 19 Treatment of Tuberculosis, American Thoracic 4. Principles of Antituberculosis Chemotherapy .................. 32 Society, CDC, and Infectious Diseases Society of America. MMWR 2003;52(No. RR-11):[inclusive 5. Recommended Treatment Regimens .............................. 36 page numbers]. 6. Practical Aspects of Treatment........................................ 42 7. Drug Interactions ........................................................... 45 8. Treatment in Special Situations
    [Show full text]
  • D-Cycloserine
    D-Cycloserine Catalog Numbers: C6880, C3909, C7670 Storage Temperature –20°C CAS #: 68-41-7 Reagents Synonyms: D-4-amino-3-isoxazolidone, D-oxamycin, These products are supplied as powders. Seromycin, K300, NJ-21 C7670 is convenience packaged for use in molecular Product Description biology; it is pre-weighed in quantities to give typical Appearance: White powder working concentrations when the entire package is Molecular Formula: C3H6N2O2 added to 1 L of agar preparations (for 50 plates of 20 ml Molecular Weight: 102.09 per plate). Furthermore, C 7670 is g-irradiated for E 1% = 402 (226 nm) sterility and septum-capped for ease in injecting sterile 23 1 [a]D = +115° (c=1.0%, water) diluent. C 7670 is also USP tested for potency following g-irradiation to assure full biological activity. D-Cycloserine, a structural analog of D-alanine, is a broad spectrum antibiotic produced by certain strains of Preparation Instructions Streptomyces orchidaceus or S. garphalus.1-5 D-cyclo- D-cycloserine is soluble in deionized water up to serine (at 100-200 mg/ml) inhibits the synthesis of 100 mg/ml. A solution of 50 mg/ml cycloserine in water bacterial cell walls (involving peptidoglycan synthesis) is clear and colorless or very faintly yellow. by preventing formation of D-alanine from L-alanine and D-cycloserine is also soluble at 1 in 50 parts of 96% hence the formation of peptide bonds involving ethanol, but practically insoluble in chloroform and D-alanine.4 D-cycloserine has antibiotic activity in vitro ether. It is also slightly soluble in methanol or propylene against growth phase Gram-negative bacteria including glycol.
    [Show full text]
  • The Impact of D-Cycloserine and Sarcosine on in Vivo Frontal Neural
    Yao et al. BMC Psychiatry (2019) 19:314 https://doi.org/10.1186/s12888-019-2306-1 RESEARCH ARTICLE Open Access The impact of D-cycloserine and sarcosine on in vivo frontal neural activity in a schizophrenia-like model Lulu Yao1, Zongliang Wang1, Di Deng1, Rongzhen Yan1, Jun Ju1 and Qiang Zhou1,2* Abstract Background: N-methyl-D-aspartate receptor (NMDAR) hypofunction has been proposed to underlie the pathogenesis of schizophrenia. Specifically, reduced function of NMDARs leads to altered balance between excitation and inhibition which further drives neural network malfunctions. Clinical studies suggested that NMDAR modulators (glycine, D-serine, D-cycloserine and glycine transporter inhibitors) may be beneficial in treating schizophrenia patients. Preclinical evidence also suggested that these NMDAR modulators may enhance synaptic NMDAR function and synaptic plasticity in brain slices. However, an important issue that has not been addressed is whether these NMDAR modulators modulate neural activity/spiking in vivo. Methods: By using in vivo calcium imaging and single unit recording, we tested the effect of D-cycloserine, sarcosine (glycine transporter 1 inhibitor) and glycine, on schizophrenia-like model mice. Results: In vivo neural activity is significantly higher in the schizophrenia-like model mice, compared to control mice. D-cycloserine and sarcosine showed no significant effect on neural activity in the schizophrenia-like model mice. Glycine induced a large reduction in movement in home cage and reduced in vivo brain activity in control mice which prevented further analysis of its effect in schizophrenia-like model mice. Conclusions: We conclude that there is no significant impact of the tested NMDAR modulators on neural spiking in the schizophrenia-like model mice.
    [Show full text]
  • Neuroenhancement in Healthy Adults, Part I: Pharmaceutical
    l Rese ca arc ni h li & C f B o i o l e Journal of a t h n Fond et al., J Clinic Res Bioeth 2015, 6:2 r i c u s o J DOI: 10.4172/2155-9627.1000213 ISSN: 2155-9627 Clinical Research & Bioethics Review Article Open Access Neuroenhancement in Healthy Adults, Part I: Pharmaceutical Cognitive Enhancement: A Systematic Review Fond G1,2*, Micoulaud-Franchi JA3, Macgregor A2, Richieri R3,4, Miot S5,6, Lopez R2, Abbar M7, Lancon C3 and Repantis D8 1Université Paris Est-Créteil, Psychiatry and Addiction Pole University Hospitals Henri Mondor, Inserm U955, Eq 15 Psychiatric Genetics, DHU Pe-psy, FondaMental Foundation, Scientific Cooperation Foundation Mental Health, National Network of Schizophrenia Expert Centers, F-94000, France 2Inserm 1061, University Psychiatry Service, University of Montpellier 1, CHU Montpellier F-34000, France 3POLE Academic Psychiatry, CHU Sainte-Marguerite, F-13274 Marseille, Cedex 09, France 4 Public Health Laboratory, Faculty of Medicine, EA 3279, F-13385 Marseille, Cedex 05, France 5Inserm U1061, Idiopathic Hypersomnia Narcolepsy National Reference Centre, Unit of sleep disorders, University of Montpellier 1, CHU Montpellier F-34000, Paris, France 6Inserm U952, CNRS UMR 7224, Pierre and Marie Curie University, F-75000, Paris, France 7CHU Carémeau, University of Nîmes, Nîmes, F-31000, France 8Department of Psychiatry, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Eschenallee 3, 14050 Berlin, Germany *Corresponding author: Dr. Guillaume Fond, Pole de Psychiatrie, Hôpital A. Chenevier, 40 rue de Mesly, Créteil F-94010, France, Tel: (33)178682372; Fax: (33)178682381; E-mail: [email protected] Received date: January 06, 2015, Accepted date: February 23, 2015, Published date: February 28, 2015 Copyright: © 2015 Fond G, et al.
    [Show full text]
  • CYCLOSERINE Proposal for Revision of the International Pharmacopoeia (August 2012)
    Working document QAS/12.463 August 2012 RESTRICTED CYCLOSERINE Proposal for revision of The International Pharmacopoeia (August 2012) Draft for comment This document was provided by a quality control expert. Should you have any comments thereon, please send these to Dr Herbert Schmidt, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, World Health Organization, 1211 Geneva 27, Switzerland; fax: (+41 22) 791 4730 or e-mail: [email protected] with a copy to [email protected] by 17 September 2012. In order to speed up the process for receiving draft monographs and for sending comments, please let us have your e-mail address (to [email protected] ) and we will add it to our electronic mailing list. Please specify if you wish to receive monographs. © World Health Organization 2012 All rights reserved. This draft is intended for a restricted audience only, i.e. the individuals and organizations having received this draft. The draft may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means outside these individuals and organizations (including the organizations' concerned staff and member organizations) without the permission of the World Health Organization. The draft should not be displayed on any web site. Please send any request for permission to: Dr Sabine Kopp, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, Department of Essential Medicines and Health Products , World Health Organization, CH-1211 Geneva 27, Switzerland. Fax: (41-22) 791 4730; e-mail: [email protected] . The designations employed and the presentation of the material in this draft do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
    [Show full text]
  • Structure-Based Discovery of Prescription Drugs That Interact with the Norepinephrine Transporter, NET
    Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET Avner Schlessingera,b,c,1, Ethan Geiera, Hao Fana,b,c, John J. Irwinb,c, Brian K. Shoichetb,c, Kathleen M. Giacominia, and Andrej Salia,b,c,1 aDepartment of Bioengineering and Therapeutic Sciences, bDepartment of Pharmaceutical Chemistry, and cCalifornia Institute for Quantitative Biosciences, University of California, San Francisco, CA 94158 Edited by Barry Honig, Columbia University, Howard Hughes Medical Institute, New York, NY, and approved July 20, 2011 (received for review April 15, 2011) The norepinephrine transporter (NET) transports norepinephrine transporter (SERT, SLC6A4) (4). Because of the lack of high- from the synapse into presynaptic neurons, where norepinephrine resolution structural information, most drug discovery efforts regulates signaling pathways associated with cardiovascular targeting NET and other SLC6 transporters, including SERT and effects and behavioral traits via binding to various receptors dopamine transporter (DAT,SLC6A3), have relied on quantitative (e.g., β2-adrenergic receptor). NET is a known target for a variety structure-activity relationship (QSAR) approaches and pharmaco- of prescription drugs, including antidepressants and psychosti- phore modeling (5). mulants, and may mediate off-target effects of other prescription As for other SLC6 family members, NET is predicted to have drugs. Here, we identify prescription drugs that bind NET, using one domain containing 12 transmembrane helices (2). No struc- virtual ligand screening followed by experimental validation of tures of human SLC6 members have been determined at atomic predicted ligands. We began by constructing a comparative struc- resolution; however, the leucine transporter LeuT from the bac- tural model of NET based on its alignment to the atomic structure terium Aquifex aeolicus has been determined by X-ray crystallo- of a prokaryotic NET homolog, the leucine transporter LeuT.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • 207145Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 207145Orig1s000 MEDICAL REVIEW(S) Clinical Review Leonard P. Kapcala, M.D. NDA 207145 XADAGO (SAFINAMIDE) CLINICAL REVIEW Application Type NDA Application Number 207145 Priority or Standard Standard Submit Date 9/21/16 Received Date 9/21/16 PDUFA Goal Date 3/21/17 Division / Office DNP/ODE 1 Reviewer Name Leonard P. Kapcala, M.D. Review Completion Date 2/7/17 Established Name SAFINAMIDE (Proposed) Trade Name XADAGO Therapeutic Class Monoamine Oxidase B Inhibitor Applicant Newron Formulation(s) Tablet Dosing Regimen Once daily orally Indication(s) Treatment of signs and symptoms of Parkinson's disease Intended Population(s) Patients with early and advanced Parkinson's disease 1 Reference ID: 4071416 Clinical Review Leonard P. Kapcala, M.D. NDA 207145 XADAGO (SAFINAMIDE) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 4 1.1 Recommendation on Regulatory Action ............................................................. 4 1.2 Risk Benefit Assessment .................................................................................... 4 1.3 Recommendations for Postmarket Risk Evaluation and Mitigation Strategies ... 5 1.4 Recommendations for Postmarket Requirements and Commitments ................ 5 2 INTRODUCTION AND REGULATORY BACKGROUND ........................................ 5 2.1 Product Information (Based Upon Sponsor Summary) ....................................... 5 2.2 Other Relevant Background Information ...........................................................
    [Show full text]
  • World Health Organization Model List of Essential Medicines, 21St List, 2019
    World Health Organizatio n Model List of Essential Medicines 21st List 2019 World Health Organizatio n Model List of Essential Medicines 21st List 2019 WHO/MVP/EMP/IAU/2019.06 © World Health Organization 2019 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. World Health Organization Model List of Essential Medicines, 21st List, 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.
    [Show full text]
  • Treatment for Cocaine Addiction
    (19) TZZ¥_Z_T (11) EP 3 170 499 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 24.05.2017 Bulletin 2017/21 A61K 31/27 (2006.01) A61K 31/16 (2006.01) A61P 25/00 (2006.01) (21) Application number: 16204193.3 (22) Date of filing: 31.08.2011 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • LEDERMAN, Seth GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO New York, NY 10022 (US) PL PT RO RS SE SI SK SM TR • HARRIS, Herbert New York, NY 10022 (US) (30) Priority: 01.09.2010 US 379095 P (74) Representative: Bassil, Nicholas Charles et al (62) Document number(s) of the earlier application(s) in Kilburn & Strode LLP accordance with Art. 76 EPC: 20 Red Lion Street 11832859.0 / 2 611 440 London WC1R 4PJ (GB) (71) Applicant: Tonix Pharmaceuticals, Inc. Remarks: New York, NY 10022 (US) This application was filed on 14.12.2016 as a divisional application to the application mentioned under INID code 62. (54) TREATMENT FOR COCAINE ADDICTION (57) A novel pharmaceutical composition is provided therapeutic dose application or a single dose of a com- for the control of stimulant effects, in particular treatment bined therapeutically effective composition of disulfiram of cocaine addiction, or further to treatment of both co- and selegiline compounds or pharmaceutically accepta- caine and alcohol dependency, including simultaneous ble non-toxic salt thereof. EP 3 170 499 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 3 170 499 A1 2 Description and MDMA (3,4-methylenedioxymethamphetamine), better
    [Show full text]
  • Vesterinen2013.Pdf
    This thesis has been submitted in fulfilment of the requirements for a postgraduate degree (e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following terms and conditions of use: This work is protected by copyright and other intellectual property rights, which are retained by the thesis author, unless otherwise stated. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author. The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author. When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given. Systematic review and meta-analysis of experimental multiple sclerosis studies Hanna Mikaela Vesterinen BSc (Hons) PhD by Research 2013 Abstract Background: Multiple sclerosis (MS) is the most common cause of disability in young people and yet there are no interventions available which reliably alter disease progression. This is despite several decades of research using the most common animal model of multiple sclerosis, experimental autoimmune encephalomyelitis (EAE). There is now emerging evidence across the neurosciences to suggest that limited internal validity (measures to reduce bias) and external validity (e.g. using a clinically relevant animal model) may influence the translational success. Aim and objectives: To provide an unbiased summary of the scope of the literature on candidate drugs for MS tested in EAE to identify potential reasons for the failures to translate efficacy to clinical trials.
    [Show full text]